New treatment for pain caused by chemotherapy
Novel biologic to treat chemotherapy-induced neuropathic pain
This study is testing a new treatment called RFT1081 to help cancer patients who are dealing with painful nerve issues caused by chemotherapy, aiming to ease their pain without the usual side effects of pain meds.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Raft Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10706551 on NIH RePORTER |
What this research studies
This research investigates a novel biologic treatment aimed at alleviating chemotherapy-induced peripheral neuropathy (CIPN), which affects many cancer patients. The approach focuses on a candidate drug, RFT1081, that targets specific cells involved in pain signaling and inflammation. By modifying the lipid composition of these cells, the treatment seeks to reduce chronic pain without the side effects associated with traditional pain medications. Patients may receive this treatment through a direct spinal delivery method, which has shown promise in preclinical studies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients experiencing chronic pain due to chemotherapy-induced peripheral neuropathy.
Not a fit: Patients who are not undergoing chemotherapy or do not experience neuropathic pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective long-term solution for managing pain in cancer patients undergoing chemotherapy.
How similar studies have performed: Previous research has shown promise in targeting neuroinflammation for pain relief, making this approach a potentially innovative advancement in pain management.
Where this research is happening
San Diego, United States
- Raft Pharmaceuticals, LLC — San Diego, United States (Active)
Researchers
- Principal investigator: Kogan, Yakov — Raft Pharmaceuticals, LLC
- Study coordinator: Kogan, Yakov
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.